FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 379 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Cancer in My Community: Providing Free Access to Cancer Care in... September 17, 2020 For Some Kids with Brain Cancer, Targeted Therapy is Better than... June 29, 2022 6 things you need to know about cervical screening October 25, 2021 Immunotherapy after Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer March 21, 2023 Load more HOT NEWS Bringing the Cancer Community Back Together at ASCO Annual Meeting: Why... FDA Approves Abatacept for Prophylaxis of Acute Graft Versus Host Disease Cancer in My Community: Overcoming Inequities in Care in Argentina News digest – smoking ban, HPV and prostate cancer, genetic testing...
